Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study

Key Points Patients with iTTP in remission had pathologically increased blood–brain barrier permeability, which improved but did not resolve 6 months later.

[1]  L. Cucullo,et al.  A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity , 2020, Fluids and barriers of the CNS.

[2]  L. Cipolotti,et al.  Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura , 2020, British journal of haematology.

[3]  C. Tamminga,et al.  Molecular adaptations of the blood–brain barrier promote stress resilience vs. depression , 2020, Proceedings of the National Academy of Sciences.

[4]  M. Streiff,et al.  Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. , 2019, Blood.

[5]  A. Fagan,et al.  Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction , 2018, Nature Medicine.

[6]  Flora Peyvandi,et al.  Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura , 2019, The New England journal of medicine.

[7]  Ting-Yim Lee,et al.  CT Perfusion Techniques and Applications in Stroke and Cancer , 2019 .

[8]  H. An,et al.  Silent infarcts in sickle cell disease occur in the border zone region and are associated with low cerebral blood flow. , 2018, Blood.

[9]  M. Chopp,et al.  Blood–Brain Barrier Disruption, Vascular Impairment, and Ischemia/Reperfusion Damage in Diabetic Stroke , 2017, Journal of the American Heart Association.

[10]  Ting-Yim Lee,et al.  Quantification of blood-brain barrier permeability by dynamic contrast-enhanced NIRS , 2017, Scientific Reports.

[11]  B. Lämmle,et al.  Depression and cognitive deficits as long‐term consequences of thrombotic thrombocytopenic purpura , 2017, Transfusion.

[12]  P. Coppo,et al.  Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies , 2017, Journal of thrombosis and haemostasis : JTH.

[13]  James G. Scott,et al.  Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura , 2015, American journal of hematology.

[14]  C. Abrams,et al.  How I treat refractory thrombotic thrombocytopenic purpura. , 2015, Blood.

[15]  Mayra Vargas-Rivera,et al.  Platelets Contribute to BBB Disruption Induced by HIV and Alcohol , 2015, Journal of alcoholism and drug dependence.

[16]  G. Ortiz,et al.  Role of the blood-brain barrier in multiple sclerosis. , 2014, Archives of medical research.

[17]  S. Ferrari,et al.  Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura , 2014, Haematologica.

[18]  S. Vesely,et al.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. , 2013, Blood.

[19]  Chun-Jung Juan,et al.  Effects of Microvascular Permeability Changes on Contrast-Enhanced T1 and Pharmacokinetic MR Imagings After Ischemia , 2013, Stroke.

[20]  Ting-Yim Lee,et al.  The effect of scan duration on the measurement of perfusion parameters in CT perfusion studies of brain tumors. , 2013, Academic radiology.

[21]  F. Peyvandi,et al.  Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies , 2012, British journal of haematology.

[22]  Jiang Hsieh,et al.  Quantitative myocardial perfusion measurement using CT Perfusion: a validation study in a porcine model of reperfused acute myocardial infarction , 2012, The International Journal of Cardiovascular Imaging.

[23]  A. Chandler,et al.  Reproducibility of CT perfusion parameters in liver tumors and normal liver. , 2011, Radiology.

[24]  J. Hsieh,et al.  Non-invasive assessment of functionally relevant coronary artery stenoses with quantitative CT perfusion: preliminary clinical experiences , 2011, European Radiology.

[25]  J. George,et al.  How I treat patients with thrombotic thrombocytopenic purpura: 2010. , 2010, Blood.

[26]  Ting-Yim Lee,et al.  Hemorrhagic Transformation of Ischemic Stroke: Prediction with CT , 2009 .

[27]  J. George.  The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989-2007). , 2009, Kidney international. Supplement.

[28]  J. Sontrop,et al.  Treating TTP/HUS with plasma exchange: a single centre’s 25‐year experience , 2008, British journal of haematology.

[29]  Ting-Yim Lee,et al.  Hepatic perfusion in a tumor model using DCE-CT: an accuracy and precision study , 2008, Physics in medicine and biology.

[30]  J. George,et al.  Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long‐term follow‐up with serial analysis of ADAMTS13 activity , 2007, British journal of haematology.

[31]  B. Löwenberg,et al.  Splenectomy for the treatment of thrombotic thrombocytopenic purpura , 2005, British journal of haematology.

[32]  W. Miesbach,et al.  The course of ADAMTS‐13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine , 2005, British journal of haematology.

[33]  Iwao Kanno,et al.  Database of normal human cerebral blood flow, cerebral blood volume, cerebral oxygen extraction fraction and cerebral metabolic rate of oxygen measured by positron emission tomography with 15O-labelled carbon dioxide or water, carbon monoxide and oxygen: a multicentre study in Japan , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  Alireza Minagar,et al.  Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.

[35]  T-Y Lee,et al.  CT imaging of angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[36]  Iwao Kanno,et al.  Regional distribution of human cerebral vascular mean transit time measured by positron emission tomography , 2003, NeuroImage.

[37]  W. Clark,et al.  Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. , 2001, Haematologica.

[38]  J. George.  How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. , 2000, Blood.

[39]  R. Aster,et al.  Thrombotic thrombocytopenic purpura: Early and late responders , 1997, American journal of hematology.

[40]  R. Holman,et al.  Increasing mortality from thrombotic thrombocytopenic purpura in the United States—analysis of national mortality data, 1968–1991 , 1995, American journal of hematology.

[41]  L. Mccarthy,et al.  Thrombotic thrombocytopenic purpura: A neurological perspective. , 1995, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[42]  J. Kelton,et al.  Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura , 1992 .

[43]  G. Hutchins,et al.  The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. , 1979, Annals of internal medicine.

[44]  J. Ultmann,et al.  THROMBOTIC THROMBOCYTOPENIC PURPURA: REPORT OF 16 CASES AND REVIEW OF THE LITERATURE , 1966 .